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Purpose To investigate whether the use of pre-orchiectomy instead of pre-chemotherapy tumor 
marker (TM) levels has an impact on the International Germ Cell Consensus Classification 
(IGCCCG) risk group assignment in patients with metastatic germ cell tumors (GCT). 
Methods Demographic and clinical information of all patients treated for primary metastatic 
testicular non-seminomatous GCT in our tertiary care academic center were extracted from 
medical charts. IGCCCG risk group assignment was correctly performed with pre-
chemotherapy marker levels and additionally with pre-orchiectomy marker levels. Agreement 
between pre-chemotherapy and pre-orchiectomy risk group assignments was assessed using 
Cohen’s kappa. 
Results Our cohort consisted of 83 patients. The use of pre-orchiectomy TMs resulted in an 
IGCCCG risk group upstaging in 12 patients (16%, 8 patients from good- to intermediate-risk 
and 4 patients from intermediate- to poor-risk) and a downstaging in 1 patient (1.2%, from 
intermediate- to good-risk). The agreement between pre-orchiectomy and pre-chemotherapy 
IGCCCG risk groups resulted in a Cohen’s kappa of 0.888 (p<0.001). 
Conclusions Using pre-orchiectomy TMs can result in incorrect IGCCCG risk group 
assignment, which in turn can impact on the clinical management and follow-up of patients 
with metastatic GCT. Thus, adherence to the IGCCCCG standard using pre-chemotherapy TMs 
levels is recommended. 
Keywords: testicular germ cell tumor; Biomarkers, Tumor; prognosis 
Introduction 
One third of all patients presenting with testicular germ cell tumors (GCT) have metastases at 
initial diagnosis (DeSantis et al. 2014). An additional 15 - 30% of patients with initially 
localised disease will develop metastatic disease during follow-up (Chung et al. 2015; Daugaard 
et al. 2014). In 1997, the International Germ Cell Cancer Cooperative Group (IGCCCG) 
published a prognostic classification system, which is based on the histological subtype 
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(seminoma vs. non-seminoma), the location of the primary tumor, the extent of metastatic 
spread as well as the level of the pre-chemotherapy tumor markers (TM) alpha-fetoprotein 
(AFP), human chorionic gonadotropin (bHCG) and lactate dehydrogenase (LDH) 
(International-Germ-Cell-Cancer-Collaborative-Group 1997). In clinical practice, the IGCCCG 
risk group assignment is sometimes incorrectly performed by using pre-orchiectomy instead of 
pre-chemotherapy TM levels. This mistake may have impact on the treatment and follow-up 
intensity and thus, on the oncological outcome.  
The aim of our investigation was to assess whether the use of pre-orchiectomy instead of pre-
chemotherapy TM levels has an impact on the IGCCCG risk group assignment and thus 
intensity of treatment in patients with metastatic testicular GCT. 
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Patients and methods 
We identified patients who underwent first-line chemotherapy for primary metastatic non-
seminomatous GCT of the testis in our institution between 1991 and 2015. Patients with 
extragonadal GCTs, bilateral testicular GCTs or missing follow-up information were excluded 
from our analysis. Pre-chemotherapy baseline characteristics (age, histology of the primary 
tumor, site and extent of metastases) and pre-orchiectomy and pre-chemotherapy TM levels 
were retrieved from electronic medical records as both assessments are clinical routine at our 
center. 
IGCCCG risk group assignment was correctly performed with pre-chemotherapy TM levels 
and compared to the incorrect one based on pre-orchiectomy TM levels. Agreement between 
pre-chemotherapy and pre-orchiectomy IGCCCG risk group assignments was assessed using 
Cohen’s kappa. An kappa of 0.61-0.8 was interpreted as substantial and 0.81-1.00 as an 
excellent agreement (Landis and Koch 1977). 
Statistical analyses were performed using SPSS Statistics version 21.0 (IBM Corp., Armonk, 
New York, USA). The results for continuous normally distributed variables are expressed as 
mean ± standard deviation (SD). Continuous non-normally distributed variables are presented 
as median and interquartile ranges (IQR) and categorical variables are presented as number and 
percent. All p-values <0.05 were considered statistically significant. All statistical tests were 




A total of 83 patients with primary metastatic testicular non-seminomatous GCTs were 
identified. Their baseline characteristics are summarized in Table 1. TM levels changed after 
orchiectomy as follows: AFP decreased by a median of 5µg/l (IQR 0 to 108 µg/l), bHCG 
decreased with a median change of 0 U/l (IQR -5 to 235 U/l), and LDH decreased by a median 
of 82U/l (IQR 0-158 U/l). After orchiectomy AFP changed over 1000 µg/l in 11 patients, but 
only 5 patients had an AFP induced IGCCCG reclassification because patients were already 
classified as intermediate or poor risk (Figure 1 & Table 2). Similarly 14 patients had bHCG 
changes over 5000 U/l after orchiectomy but IGCCCG reclassification was observed in only 6 
patients because of the same reason. Significant changes of LDH levels >720 U/l were observed 
in 6 patients but incorrect upstaging from good to intermediate risk was documented in only 3 
patients. 
 
Fifty men (60%) were assigned to the IGCCCG good-risk group, 19 (23%) to the intermediate-
risk group, and 14 (17%) to the poor-risk group (Table 3). When pre-orchiectomy instead pre-
chemotherapy TM levels were used for IGCCCG risk group assignment, 43 patients (52%) 
were assigned to the good-risk group, 22 (27%) to the intermediate-risk group and 18 (21%) to 
the poor risk group. Pre-orchiectomy TMs resulted in an IGCCCG risk group change in 13 
patients (16%). Eight (10%) patients changed from good to intermediate risk and four (5%) 
patients from intermediate to poor-risk. One patient (1%) showed quickly rising AFP levels 
after orchiectomy. Using pre-orchiectomy TM levels would have led to an assignment to the 
good instead of intermediate-risk group. The overall agreement between pre-chemotherapy and 






Our analysis revealed that the use of pre-orchiectomy TM levels frequently results in an upgrade 
and less frequently in a downgrade of the IGCCCG risk group assignment and thus can lead to 
incorrect treatmentss and unnecessary follow-up investigations. 
Given that cancer cells in the affected testis represent a relevant source of TM production, the 
burden of metastastic disease is better represented by the pre-chemotherapy TMs after removal 
of the primary tumor. In our cohort pre-orchiectomy TM levels led to an upstaging from good 
to intermediate risk in 10% and from intermediate to poor risk in 5% of all patients. Given the 
fact that the IGCCCG classification is also used to determine the intensity of subsequent 
chemotherapy (i.e. 3 cycles for good risk and 4 cycles for intermediate and poor risk) incorrect 
classification may lead to overtreatment, which would result into unnecessary toxicity 
(Chovanec et al. 2017; Kerns et al. 2018) without an oncological benefit. Furthermore, incorrect 
upstaging may also trigger more intense follow-up investigations (e.g. more office visits, TM 
analyses and potentially harmful CT scans). On the other hand, one patient with rapidly rising 
AFP levels post-orchiectomy would have been incorrectly downstaged by pre-orchiectomy TM 
levels. Although our results indicated that only a minority of patients might be affected, 
incorrect IGCCCG risk group assignment may have also devastating consequences from 
undertreatment in individual patients. 
 
 
In conclusion, IGCCCG risk group assignment should be performed carefully to avoid 
misclassification that can result in over- and undertreatment. Based on our results we suggest 
to exclusively assign IGCCCG risk groups based on pre-chemotherapy TM levels. 
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 Table 1 Baseline characteristics 
 
 
AFP= Alpha-fetoprotein, bHCG=Beta-human chorionic gonadotropin, LDH=Lactate dehydrogenase, SD=Standard deviation 
 
  N = 83 
Age (years) (±SD) 30 (±9) 
IGCCCG risk groups 
- Good risk n (%) 
- Intermediate risk n (%) 





Site of metastases 
- Retroperitoneal lymph 
nodes 
-  Lung 
-  Mediastinal 
-  Neck 
-  Liver 
-  Bone 
-  Brain  










Pre- chemotherapy tumor 
markers levels 
AFP (µg/l)[IQR] 
bHCG (U/l) [IQR] 
LDH (U/l)[IQR] 
                          
   
53.7 [3.8 – 627.0] 
51.0 [0.0 – 2862.0] 
387 [450 – 720] 
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AFP= Alpha-fetoprotein, bHCG=Beta-human chorionic gonadotropin, IQR= interquartile range, LDH=Lactate dehydrogenase, 
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Table 2 Tumor marker change scores and reasons of patients with upstaging or downstaging of IGCCCG assignments 
AFP= Alpha-fetoprotein, bHCG=Beta-human chorionic gonadotropin, LDH=Lactate dehydrogenase (upper level of normal is 480 U/l) 
    AFP    bHCG    LDH   
Correct 
IGCCCG 



























Good Intermediate Upstaging AFP, HCG 1009.4 3.1 1006.3 1249.9 0 1249.9 524 518 6 
Good Intermediate Upstaging AFP 2294.9 567.5 1727.4 9.5 7.2 2.3 411 386 25 
Good Intermediate Upstaging AFP 4905 774.6 4130.4 13.5 0 13.5 700 445 255 
Good Intermediate Upstaging HCG 1.8 1.7 0.1 12528 3456 9072 442 329 113 
Good Intermediate Upstaging HCG 499 60.4 438.6 37401 2927 34474 432 377 55 
Intermediate Poor Upstaging AFP 31800 2760 29040 6995 3367 3628 553 438 115 
Intermediate Poor Upstaging HCG 5 3 2 65523 24313 41210 364 291 73 
Intermediate Poor Upstaging HCG 1.9 2.7 -0.8 71885 29696 42189 610 336 274 
Intermediate Poor Upstaging HCG 7 4.5 2.5 81326 9917.5 71408.5 314 179 135 
Good Intermediate Upstaging LDH 9.3 4.99 4.31 13.7 NA NA 3258 387 2871 
Good Intermediate Upstaging LDH 53.7 30.8 22.9 24 7.8 16.2 1094 466 628 
Good Intermediate Upstaging LDH 4.8 3.8 1 4 0 4 795 685 110 
Intermediate Good Downstaging AFP 529 1804 -1275 94 207 -113 172 303 -131 
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Table 3 International Germ Cell Cancer Collaborative Group (IGCCCG) risk group assignment 
using either preorchiectomy (columns) or prechemotherapy (rows) tumor marker levels. 










































Good  risk 
42 8 0 50  No change 
Intermediate 
risk 
1 14 4 19  Upstaging 
Poor risk 
0 0 14 14  Downstaging 
 43 22 18 83 




Figure 1 Waterfall plots of tumor marker decrease after orchiectomy for APF (a), HCG (b) and LDH (c) 
 
 
 
 

